Summary
Regeneron Pharmaceuticals, Inc. demonstrated robust revenue growth in 2014, reaching $2,819.6 million, an increase from $2,104.7 million in 2013, primarily driven by strong performance in its EYLEA franchise. EYLEA's net product sales in the U.S. reached $1,736.4 million in 2014, with significant international sales of $1,038.5 million contributing to overall growth. The company also reported progress in its late-stage pipeline, with key clinical trial updates for PRALUENT (alirocumab) for cholesterol reduction and sarilumab for rheumatoid arthritis, alongside ongoing development for dupilumab in allergic conditions. While net income decreased to $348.1 million ($3.07 per diluted share) in 2014 from $424.4 million ($3.81 per diluted share) in 2013, this was largely attributed to the absence of a significant tax benefit recorded in 2012. Regeneron's strategic focus remains on leveraging its VelociSuite technologies for drug discovery and expanding its therapeutic reach into areas with high unmet medical needs. The company also highlighted its human genetics initiative as a key long-term growth driver.
Financial Highlights
47 data points| Revenue | $2.82B |
| Cost of Revenue | $129.03M |
| Gross Profit | $2.69B |
| R&D Expenses | $1.27B |
| SG&A Expenses | $519.27M |
| Operating Expenses | $2.00B |
| Operating Income | $823.92M |
| Interest Expense | $37.37M |
| Net Income | $338.13M |
| EPS (Basic) | $3.36 |
| EPS (Diluted) | $2.98 |
| Shares Outstanding (Basic) | 100.61M |
| Shares Outstanding (Diluted) | 113.41M |
Key Highlights
- 1EYLEA continues to be the primary revenue driver, with U.S. sales reaching $1.74 billion and international sales by Bayer HealthCare exceeding $1.04 billion in 2014.
- 2The company reported total revenues of $2.82 billion in 2014, a significant increase from $2.10 billion in 2013, showcasing strong top-line growth.
- 3Regeneron has a substantial pipeline with 17 product candidates in clinical development, including key late-stage programs like PRALUENT (PCSK9 inhibitor) and sarilumab (IL-6R antibody).
- 4The company initiated several Phase 3 clinical trials for dupilumab, targeting atopic dermatitis, asthma, and chronic sinusitis with nasal polyps, indicating aggressive advancement of its antibody-based pipeline.
- 5Collaboration revenue from Sanofi and Bayer HealthCare was substantial, contributing over $1 billion to total revenues, underscoring the importance of strategic partnerships.
- 6Research and development expenses increased significantly to $1.27 billion in 2014, reflecting ongoing investment in pipeline development and expansion of research activities, including a new human genetics initiative.
- 7The company is subject to significant patent litigation, particularly concerning its antibody technology platforms and the PRALUENT program.